Research graph
References from Antitumor efficacy of PD-1 blocking antibody is enhanced through liposomal delivery and myeloid immune modulation. Local targets link to admitted publications; unresolved targets remain external evidence.
Association of pembrolizumab with tumor response and survival among patients with advanced melanoma
10.1001/jama.2016.4059 · 2016 · External reference
Immune checkpoint inhibitors: new insights and current place in cancer therapy
10.1002/phar.1643 · 2015 · External reference
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018 · External reference
Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody
10.1021/acs.nanolett.5b05030 · 2016 · External reference
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity
10.1080/2162402x.2015.1074374 · 2016 · External reference
Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy
10.7150/thno.30577 · 2019 · External reference
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
10.1126/scitranslmed.aan3682 · 2018 · External reference
Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies
10.2165/00003088-200342050-00002 · 2003 · External reference
Daunorubicin and cytarabine liposome in newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes
10.1177/1060028018764923 · 2018 · External reference
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications
10.1016/s1567-5769(02)00271-0 · 2003 · External reference
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy
10.1073/pnas.88.24.11460 · 1991 · External reference
Cancer nanomedicine: a review of recent success in drug delivery
10.1186/s40169-017-0175-0 · 2017 · External reference
What we need to know about liposomes as drug nanocarriers: an updated review
2023 · External reference
Immune implications of cholesterol-containing lipid nanoparticles
10.1021/acsnano.4c06369 · 2024 · External reference
Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective
2025 · External reference
Pegylated liposomal alendronate biodistribution, immune modulation, and tumor growth inhibition in a murine melanoma model
10.3390/biom13091309 · 2023 · External reference
Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment
10.1002/ijc.27755 · 2013 · External reference
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
10.1172/jci28828 · 2006 · External reference
The tumor-draining lymph node as an immune-privileged site
10.1111/j.1600-065x.2006.00444.x · 2006 · External reference
Tumor-induced CD11b+gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes
10.4049/jimmunol.181.5.3291 · 2008 · External reference
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
10.3389/fimmu.2022.964442 · 2022 · External reference
Differential role of PD-1 expressed by various immune and tumor cells in the tumor immune microenvironment: expression, function, therapeutic efficacy, and resistance to cancer immunotherapy
10.3389/fcell.2021.767466 · 2021 · External reference
Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer
10.1038/s41467-022-29366-6 · 2022 · External reference
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
10.1016/j.ccell.2021.09.010 · 2021 · External reference
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
10.1186/s12943-023-01725-x · 2023 · External reference
Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression
10.3389/fimmu.2022.874589 · 2022 · External reference
Macrophages in immunoregulation and therapeutics
10.1038/s41392-023-01452-1 · 2023 · External reference
Defects in macrophage reprogramming in cancer therapy: the negative impact of PD-L1/PD-1
10.3389/fimmu.2021.690869 · 2021 · External reference
Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer
10.3892/or.2022.8284 · 2022 · External reference
A comparison of murine PD-1 and PD-L1 monoclonal antibodies
10.1089/mab.2021.0068 · 2022 · External reference
Thin-film hydration followed by extrusion method for liposome preparation
10.1007/978-1-4939-6591-5_2 · 2017 · External reference
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
2023 · External reference
Improving the stability of maleimide-thiol conjugation for drug targeting
10.1002/chem.202003951 · 2020 · External reference
Targeting human thrombus by liposomes modified with anti-fibrin protein binders
10.3390/pharmaceutics11120642 · 2019 · External reference
Simple and rapid quantification of phospholipids for supramolecular membrane transport assays
10.1039/c5ob02480c · 2016 · External reference
A simplification of the protein assay method of Lowry et al. which is more generally applicable
10.1016/0003-2697(77)90043-4 · 1977 · External reference
Immune modulatory oxysterols produced from cholesterol-containing lipid nanoparticles regulate tumor growth
10.1021/acsnano.5c22020 · 2026 · External reference
Quantification of pharmacokinetic profiles of PD-1/PD-L1 antibodies by validated ELISAs
10.3390/pharmaceutics12060595 · 2020 · External reference
A multimodal drug-diet-immunotherapy combination restrains melanoma progression and metastasis
10.1158/0008-5472.can-23-1635 · 2024 · External reference
Preclinical pharmacokinetics and dosimetry of an (89)Zr labelled anti-PDL1 in an orthotopic lung cancer murine model
2021 · External reference
Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
10.7150/ntno.75045 · 2022 · External reference
Surface engineering of liposomes for stealth behavior
10.3390/pharmaceutics5040542 · 2013 · External reference
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
10.1136/jitc-2019-000400 · 2020 · External reference
The role of granulocyte colony-stimulating factor in breast cancer development: a review
2020 · External reference
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know
10.1038/sj.cr.7310017 · 2006 · External reference
TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity
10.1038/s41435-024-00274-7 · 2024 · External reference
Platelet factor 4: a mysterious chemokine in inflammatory regulation diseases
10.2147/jir.s504673 · 2025 · External reference
Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis
10.1182/blood-2014-04-570762 · 2014 · External reference
The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells
10.1016/j.immuni.2013.02.011 · 2013 · External reference
Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts
10.1111/1523-1747.ep12286457 · 1997 · External reference
CXCL1/KC and CXCL5/LIX are selectively produced by corneal fibroblasts and mediate neutrophil infiltration to the corneal stroma in LPS keratitis
10.1189/jlb.0806502 · 2007 · External reference
Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment
10.1158/0008-5472.can-18-3208 · 2019 · External reference
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
10.1038/s41392-025-02124-y · 2025 · External reference
Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination
10.1073/pnas.1108945108 · 2011 · External reference
Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment
10.1038/s41467-022-29388-0 · 2022 · External reference
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment
10.1073/pnas.1720948115 · 2018 · External reference
Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers
10.1080/2162402x.2022.2131084 · 2022 · External reference
Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors
10.1136/jitc-2024-008979 · 2025 · External reference
Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth
10.1016/j.cell.2015.08.052 · 2015 · External reference
New insights into the important roles of tumor cell-intrinsic PD-1
10.7150/ijbs.60114 · 2021 · External reference
Targeted liposomal drug delivery to monocytes and macrophages
10.1155/2011/727241 · 2011 · External reference
Harnessing liposome interactions with the immune system for the next breakthrough in Cancer drug delivery
10.3389/fphar.2019.00220 · 2019 · External reference
Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity
10.1097/01.cji.0000190169.61416.f5 · 2006 · External reference
Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate
10.1016/j.jconrel.2017.12.023 · 2018 · External reference
Downregulation of EGFR by a novel multivalent nanobody-liposome platform
10.1016/j.jconrel.2010.03.020 · 2010 · External reference
Multivalent atezolizumab-liposome conjugates as active immunotherapeutic platforms for enhanced PD-L1 blockade in melanoma
2026 · External reference
Neonatal fc receptor expression in macrophages is indispensable for IgG homeostasis
10.1080/19420862.2019.1602459 · 2019 · External reference
Nanoparticle-induced complement activation: implications for cancer nanomedicine
2020 · External reference
Complement activation by drug carriers and particulate pharmaceuticals: principles, challenges and opportunities
10.1016/j.addr.2020.04.012 · 2020 · External reference
Cytotoxic mechanisms of immunotherapy: harnessing complement in the action of anti-tumor monoclonal antibodies
10.1016/j.smim.2016.03.003 · 2016 · External reference
Complement system in tumor growth and metastases
2025 · External reference
Tunable complement activation by particles with variable size and Fc density
10.1142/s1793984413410018 · 2013 · External reference
Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen
10.1016/j.molcel.2016.05.016 · 2016 · External reference
G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
10.1136/jitc-2020-002259 · 2021 · External reference
GM-CSF promotes antitumor immunity by inducing Th9 cell responses
10.1158/2326-6066.cir-18-0518 · 2019 · External reference
Tumor microenvironment and myeloid-derived suppressor cells
10.1007/s12307-012-0126-7 · 2013 · External reference
Tumor-induced myeloid-derived suppressor cells
10.1128/microbiolspec.mchd-0016-2015 · 2016 · External reference
Therapeutic potential of interleukin-21 in cancer
10.3389/fimmu.2024.1369743 · 2024 · External reference
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
10.1126/sciimmunol.aay1863 · 2020 · External reference
